|
 |
 Home > Available Issues |
|
|
 Original Articles |
| Antimicrobial Susceptibilites of Glycopeptides, Arbekacin and Quinupristin/Dalfopristin against Staphylococcal aureus isolates |
| Seung Hee Ha, M.D., Seok Hoon Jeong, M.D.*,∥, Tae Sik Jeong, M.D.†, Dae Young Seo, M.D.‡
Chulhun Chang, M.D.§, Hee Jun Nam, M.T.*, Young Woon Baek, M.D. and Jong Heaon Ji, M.D. |
| Department of Pediatrics, Clinical Pathology* and Therapeutic Radiology†, College of Medicine,
Kosin University, Pusan, Department of Clinical Pathology‡, College of Medicine, Dong-A University, Pusan,
Department of Clinical Pathology§, College of Medicine, Busan University, Pusan,
Research Institute of Bacterial Resistance∥, College of Medicine, Yonsei University, Seoul, Korea |
Vol.33 Num.4 (p261~266)
|
|
|
Background:Glycopeptides have been widely used for the treatment of severe infections caused by methicillin-resistant S. aureus (MRSA), but recently S. aureus isolates with decreased susceptibility to these antibiotics have been reported. Arbekacin and quinupristin/dalfopristin (Q/D) have been reported as effective antibiotics against MRSA infections, and these drugs are expected as useful alternatives of glycopeptides. The purposes of this study were to investigate the prevalance of S. aureus isolates with decreased susceptibility to glycopeptides in Korea, and to evaluate the antimicrobial activities of arbekacin and Q/D against this microorganism.
Methods:Antimicrobial susceptibilities of MRSA (328) and methicillin-susceptible S. aureus (39) isolates from the patients of Kosin Medical Center (KMC) were determined by NCCLS disk diffusion method. MICs of oxacillin, vancomycin, teicoplanin, arbekacin and Q/D were determined by agar dilution method.
Results:Over 90% of MRSA isolates were resistant to clindamycin, erythromycin, penicillin G and ciprofloxacin, but only 5% and 22% were resistant to trimethoprim/sulfamethoxazole and fusidic acid, respectively. Ten percents (32/328) of MRSA isolates showed decreased susceptibility to teicoplanin. MRSA isolates with this resistance phenotype were more prevalant in hospitalized patients than outpatients, and patients of medical wards than surgical wards. All the isolates were susceptible to arbekacin (MIC ≤1 μg/mL) and Q/D (MIC ≤2 μg/mL).
Conclusion:One isolate of MRSA with intermediate resistance to vancomycin from clinical specimen has been reported domestically in 1999, but MRSA strains with this resistance phenotype are not isolated in this study. But 10% (32/328) of MRSA showed decreased susceptibility to teicoplanin and this resistance prevalance is remarkably high than 1% (1/78) 1998 in KMC. Arbekacin and Q/D had excellent antimicrobial activities to the S. aureus isolates and considered that can be used as alternative drugs for glycopeptides. |
|
|
Keywords : Staphylococcus aureus, Glycopeptides, Arbekacin, Quinupristin/Dalfopristin |
|
|
|
|
|
|
|
|
